Prospective randomized clinical trial evaluating the impact of vinegar on lipids in non-diabetics


Background: Heart disease is now considered an inflammatory process targeted primarily by medical therapy on lipid levels. Complementary and alternative medicine searches for novel non-pharmacologic therapy, including pursuing various diets. Animal studies and consumer literature suggest benefits of vinegar on lipid levels and diabetes mellitus. Our nonrandomized pilot study from our group suggested a benefit in raising high-density lipoprotein cholesterol (HDL-C). Based on this data, we conducted a randomized placebo controlled clinical trial to determine the effects of apple cider vinegar intake in those without diabetes mellitus on total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides, HDL-C, Hemoglobin A1C(Hgb-A1C) and measurement of inflammation with high sensitivity CRP levels (HS-CRP). Methods: A prospective randomized, double blind, placebo-controlled clinical trial consisting of 114 participants was conducted. Participants consumed 30 mL of either apple cider vinegar or placebo for two months. Measurements were collected at baseline, eight and sixteen weeks. The primary endpoint was the change in HDL-C from baseline to eight weeks between the vinegar and placebo groups. Secondary endpoints were change from baseline to eight weeks in TC, LDL-C, triglycerides, Hgb-A1cand HS-CRP. Results: Change in serum HDL-C concentration was not significantly different between the vinegar and control groups after eight weeks of supplementation. Secondary endpoints including TC, LDL-C, Hgb-A1cand HS-CRP were not statistically different at the Bonferroni corrected significance level of 0.01. No significant difference was found regardless of baseline HDL-C levels. Conclusions: We found no significant difference in HDL-C, LDL-C, triglycerides, total cholesterol, or HS-CRP levels with use of vinegar but a trend down of Hgb-A1cin this group of non-diabetic participants. Further investigation is required to define the impact of vinegar in those with diabetes mellitus.

Share and Cite:

Panetta, C. , Jonk, Y. and Shapiro, A. (2013) Prospective randomized clinical trial evaluating the impact of vinegar on lipids in non-diabetics. World Journal of Cardiovascular Diseases, 3, 191-196. doi: 10.4236/wjcd.2013.32027.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Li, C., Balluz, L.S., Okoro, C.A., et al. (2011) Centers for disease control and prevention (CDC). Surveillance of certain health behaviors and conditions among states and selected local areas—Behavioral Risk Factor Surveillance System, United States, 2009. MMWR Surveillance Summaries, 60, 1-250.
[2] Heron, M., Hoyert, D.L., Murphy, S.L., et al. (2009) Deaths: Final data for 2006. National Vital Statistics Reports, 57, 1-134.
[3] Gordon, T., Castelli, W.P., Hjortland, M.C., et al. (1977) High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. American Journal of Medicine, 62, 707-714. doi:10.1016/0002-9343(77)90874-9
[4] Gorden, D.J., Probstfield, J.L., Garrison, R.J., et al. (1989) High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation, 79, 8-15. doi:10.1161/01.CIR.79.1.8
[5] Assmann, G. and Schults, H. (1990) Modelling the Helsinki heart study by means of risk equations obtained from the PROCAM study and the Framingham heart study. Drugs, 40, 13-18. doi:10.2165/00003495-199000401-00005
[6] Toth, P. (2004) High-density lipoprotein and Cardiovascular risk. Circulation, 109, 1809-1812. doi:10.1161/01.CIR.0000126889.97626.B8
[7] Singh, I.M., Shishehbor, M.H. and Ansell, B.J. (2007) High-density lipoprotein as a therapeutic target. A Systemic Review. JAMA, 298, 786-798. doi:10.1001/jama.298.7.786
[8] Barter, P., Gotto, A.M., LaRosa, J.C., et al. (2007) HDL cholesterol, very low levels of LDL cholesterol, and Cardiovascular events. New England Journal of Medicine, 357, 1301-1310. doi:10.1056/NEJMoa064278
[9] Carlson, L.A. (2006) Nicotinic acid and other therapies for raising high-density lipoprotein. Current Opinion in Cardiology, 21, 336.
[11] Nissen, S.E., Tsunoda, T., Tuzcu, M. et al. (2003) Effect of recombinany ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA, 290, 2292-2300. doi:10.1001/jama.290.17.2292
[12] Tardif, J.C., Gregoir, J., L’Allier, P.L., et al. (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis. A randomized controlled trial. JAMA, 297, 1675-1682. doi:10.1001/jama.297.15.jpc70004
[13] Brousseau, M.E., Schafer, E.J., Wolfe, M.L., et al. (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. New England Journal of Medicine, 350, 1505-1515. doi:10.1056/NEJMoa031766
[14] Van der Gaag, M.S., van Tol, A., Vermunt, S.H.F., et al. (2001) Alchohol consumption stimulates early steps in reverse cholesterol transport. Journal of Lipid Research, 42, 2077.
[15] Hartung, G.H., Foreyt, J.P., Mitchell, R., et al. (1983) Effect of alcohol intake on high-density lipoprotein cholesterol levels in runners and inactive men. JAMA, 249, 747-750. doi:10.1001/jama.1983.03330300031029
[16] Castelli, W.P., Doyle, J.T., Gordon, T. et al. (1977) Alcohol and blood lipids. The cooperative lipoprotein phenotyping study. Lancet, 2, 153-155. doi:10.1016/S0140-6736(77)90176-3
[17] Mukamal, K.J., Jensen, M.K., Gronbaek, M., et al. (2005) Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men. Circulation, 112, 1406-1413. doi:10.1161/CIRCULATIONAHA.105.537704
[18] Linn, S., Carroll, M., Johnson, C., et al. (1993) High- density lipoprotein cholesterol and alcohol consumption in US white and black adults: Data from NHANES II. American Journal of Public Health, 83, 811-816. doi:10.2105/AJPH.83.6.811
[19] Magnus, R., Bakke, E., Hoff, D. et al. (2011) Controlling for high-density lipoprotein cholesterol does not affect the magnitude of the relationship between alcohol and coronary heart disease. Circulation, 124, 2296-2302. doi:10.1161/CIRCULATIONAHA.111.036491
[20] Krauss, R. and Williams, P. (2011) Alcholol and the heart: Does raising high-density lipoprotein matter? Circulation, 124, 2283-2284. doi:10.1161/CIRCULATIONAHA.111.067223
[21] Moon, Y.-J. and Cha, Y.-S. (2008) Effects of persimmon- vinegar on lipid metabolism and alcohol clearance in chronic alcohol-fed rats. Journal of Medicinal Food, 11, 38-45. doi:10.1089/jmf.2007.071
[22] Sishehbor, F., Mansoori, A., Sarkaki, A.R., et al. (2008) Apple cider vinegar attenuates lipid profile in normal and diabetic rats. Pakistan Journal of Biological Sciences, 11, 2634-2638. doi:10.3923/pjbs.2008.2634.2638
[23] Setorki, M., Asgary, S., Eidi, A., et al. (2010) Acute effects of vinegar intake on some biochemical risk facgors of atherosclerosis in hypercholesterolemic rabbits. Lipids in Health and Disease, 9, 10. doi:10.1186/1476-511X-9-10
[24] Barnes, P.M., Powell-Friner, E., McFann, K., et al. (2002) Complementary and alternative medicine use among adults: United States. Advanced Data, 343, 1-19.
[25] Voelker, R. (2005) IOM points to need for more research, regulation in alternative medicine. JAMA, 293, 1178- 1180.
[26] Chan, E. (2008) Quality of efficacy research in complementary and alternative medicine. JAMA, 299, 2685-2686. doi:10.1001/jama.299.22.2685
[27] Johnston, C., Kim, C. and Buller, A. (2004) Vinegar improves insulin sensitivity to a high-carbohydrate meal in subjects with insulin resistance of type 2 diabetes. Diabetes Care, 27, 281-282. doi:10.2337/diacare.27.1.281
[28] Lind, J. (1753) A treatise of the scurvy in three parts. Containing an inquiry into the nature, causes and cure of that disease, together with a critical and chronological view of what has been published on the subject. A. Millar, London.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.